Introduction
COPD is a significant health burden worldwide and, currently, the seventh leading cause of death in Taiwan. 1 The natural history of COPD is punctuated by exacerbations, defined as acute worsening of symptoms. COPD exacerbations have been shown to be associated with an accelerated decline in pulmonary function, poorer health-related quality of life (HRQL), and higher mortality rate. 2 Involuntary weight loss is a common complication in COPD, and between 20% and 70% of patients with COPD have been reported to be underweight depending on the population studied. 3 A low body mass index (BMI) and cachexia have been associated with negative outcomes in these patients, independent of the degree of airflow limitation. [4] [5] [6] [7] Lin et al 8 reported that a cross-sectional study in Taiwan indicated that lower BMI is associated with osteoporosis in patients with COPD. However, the impact of overweight and obesity on outcomes in patients with COPD remains controversial. Some studies have reported that overweight or obesity had a protective effect against mortality in patients with COPD, 6, 7, 9 while others have reported a worse HRQL, increased severity of dyspnea and frequency of severe exacerbations in obese patients with COPD. [10] [11] [12] To the best of our knowledge, few studies have explored the relationship between overweight or obesity and the frequency of COPD exacerbations. [12] [13] [14] [15] Therefore, the aim of this study was to examine whether overweight and obesity are associated with the frequency of acute exacerbations in patients with COPD in Taiwan.
Patients and methods study design and patients
The Taiwan Obstructive Lung Disease (TOLD) study was a retrospective, observational nationwide survey of patients with COPD conducted at 12 hospitals in Taiwan (including seven medical centers and five regional hospitals) from December 2011 through November 2013. All patients enrolled in this survey were .40 years of age with a diagnosis of COPD based on the 2011 GOLD guidelines. 16 The study protocol was reviewed and approved by the individual institutional review board of each center (see 'Acknowledgment' section), and all patients provided informed consent. 
Data collection

Results
A total of 1,096 patients with COPD were included in the original TOLD study, and their demographic characteristics are summarized in Table 1 . Of these patients, 9.2%, 49.5%, 23.4%, and 17.9% were underweight, normal, overweight, and obese, respectively. The overweight and obese patients (n=452) accounted for 41.2% of all patients. Figure 1 shows the patients with few (0-1 time/year) exacerbations had a significantly higher BMI than those with the frequent exacerbator phenotype (P=0.019). In addition, the patients with a BMI $24 had fewer COPD exacerbations than those with a BMI ,24, and the lowest rate of exacerbations was observed in the overweight patients, but the differences were not statistically significant ( Figure 2 ). The patients with a higher BMI had a significantly higher rate of comorbidities (Table 2) , of which cardiovascular disease, hypertension, diabetes mellitus, ischemic heart disease, and dyslipidemia were the most common.
The results of multivariate logistic regression analysis for the frequent exacerbator phenotype are summarized in Table 3 . The wheezing phenotype and a higher mMRC score were positively associated with the frequent exacerbator phenotype, with odds ratios (ORs) of 4. 
Discussion
In this study, we retrospectively investigated the relationship between BMI and the frequency of COPD exacerbations in Taiwan. We found that overweight and obese patients with COPD were not uncommon in Taiwan and that these patients were associated with a lower frequent exacerbator phenotype. Moreover, the wheezing phenotype and a higher mMRC score were also related to this phenotype. These findings indicate that a high BMI is a predictor for a better outcome in terms of acute exacerbations in patients with COPD.
The prediction and prevention of COPD exacerbations are important goals in the management of COPD. BMI is an easily accessible parameter for patient assessment and risk stratification. It is well known that underweight increases the risk of mortality in patients with COPD. However, the impact of increased body weight on the outcomes of COPD was not conclusive. Cao et al 7 conducted a meta-analysis of 22 studies with 21,150 participants and concluded that overweight and obese COPD patients were associated with a lower risk of mortality (risk ratio [RR] 0.47, 95% CI 0.33-0.68, and 12 found that obesity was associated with worse COPD-related outcomes, including HRQL, dyspnea (mMRC score) during a 6-minute walk test, and severe exacerbations of COPD.
The results of our study are similar to a cross-sectional study reported by Cecere et al, 18 which showed a trend toward a lower frequency of COPD exacerbations in overweight or obese patients compared to normal-weight patients. Another study conducted by Jacob et al 14 also showed a lower incidence of hospitalized patient-treated exacerbations in overweight COPD patients. Other studies, however, have reported different results, such as the study of Lambert et al that reported that obesity was associated with severe exacerbations of COPD. 12 The possible explanations for the contradictory results may include differences in ethnicity, obesity levels, comorbidities, and exacerbation types. Ethnic differences may affect the role of obesity due to body fat distribution. 19 In addition, the current study compared overweight/obese patients to normal-weight patients, rather than obese patients to normal/ overweight patients in Lambert et al's study. Furthermore, different cutoff points of obese level may have interfered with the outcomes in these studies. Finally, obesity was only associated with severe but not moderate exacerbations in Lambert et al's study. However, we did not have data on the severity of the exacerbations. A large prospective cohort study conducted by Colak et al 15 showed that only genetically determined, but not observationally determined, high BMI was associated with an increased risk of recurrent exacerbations and pneumonias in individuals with COPD.
The mechanisms underlying the protection of a higher BMI against COPD exacerbations in this study are unclear. Overweight and obesity have been linked to a better prognosis in patients suffering from various chronic diseases, especially cardiovascular disease, which has been termed the obesity paradox. [20] [21] [22] [23] The mechanism responsible for this phenomenon is still unclear. 24 Circulating adipokines such as leptin and adiponectin may regulate metabolic and inflammatory systems, which play important roles in obese patients. 25 It is well known that most obese individuals have higher levels of serum leptin and lower levels of serum adiponectin compared to non-obese individuals, indicating chronic inflammation in obese patients. 26 Krommidas et al 27 reported a higher leptin/adiponectin ratio during COPD exacerbations and a lower ratio during the resolution period. However, the significance of the association between adipokines and COPD is still controversial. Wolk et al 28 reported that patients with a low BMI with a high leptin/adiponectin ratio and patients with a high BMI with a low leptin/adiponectin ratio were associated with better cardiovascular outcomes, indicating the complexity of the underlying pathophysiology. In addition, cardiorespiratory fitness and physical activity may also have positive effects on reducing deconditioning and play an important role in the obesity paradox. 29 In addition, the effects of overweight and obesity on exacerbations may be different in patients with asthma and COPD. A multicenter study of patients presented to the emergency department with asthma exacerbation showed that obese adults were at a higher risk of hospitalization compared with normal-weight adults. 30 This may reflect a difference in the perception of dyspnea, or it may reflect an underlying difference in asthma severity between the two groups. In a recent study by Denlinger et al, 31 patients with exacerbation-prone asthma (.3/year) had a higher BMI than patients with few or no exacerbations. There are several limitations to this study. First, the data were collected retrospectively, and only 12 hospitals in Taiwan were involved in the recruitment of patients in the TOLD cohort, which may lead to selection bias. However, the selection of the study sites (including medical centers and regional hospitals) and good geographic representation minimized this limitation. Second, a relatively small number of subjects with extreme and morbid obesity in the study population were involved, which may preclude the generalization of our findings to these patients. Third, BMI was used as a sole measurement of obesity in this study. The type of obesity and fat distribution, as well as the amount of visceral fat, were not assessed. Further prospective study is necessary to clarify various anthropometric parameters and their clinical relevance in COPD patients.
Conclusion
Our findings suggest that a higher BMI is a predictor of a better outcome in terms of acute exacerbations in Taiwanese patients with COPD. The lowest frequency of COPD exacerbations was observed in the overweight patients. These findings cannot be extended to patients with extreme or morbid obesity because of the small number of such patients included in this study cohort.
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